KasperSFochCMessingerD, et al.Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. Eur J Cancer2021; 144: 291–301.
2.
BensonABVenookAPAl-HawaryMM, et al.Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw2021; 19: 329–359.
3.
VecchioneLStintzingSPentheroudakisG, et al.ESMO Management and treatment adapted recommendations in the COVID-19 era: Colorectal cancer. ESMO Open2020; 5: e000826.
4.
GiulianiJBonettiA. The pharmacological costs of first-line therapies in unselected patients with advanced colorectal cancer: A review of published phase III trials. Clin Colorectal Cancer2016; 15: 277–284.
5.
ChernyNISullivanRDafniU, et al.A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol2015; 26: 1547–1573.
6.
MalmivaaraA. Generalizability of findings from randomized controlled trials is limited in the leading general medical journals. J Clin Epidemiol2019; 107: 36–41.
7.
AzimiNAWelchHG. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med1998; 13: 664.
8.
AggHHanYCuiZL. Real-world data on overall survival associated with biweekly versus weekly cetuximab among metastatic colorectal cancer (mCRC) patients in the United States. J Clin Oncol2021; 39: abstr.33.
